ArticleGynecology and pelvic medicine2026
Malignant transformation of abdominal wall endometriosis: a case report and literature review.
Article in Gynecology and pelvic medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Abdominal wall endometriosis (AWE) is a relatively rare subtype of endometriosis that has the potential for malignant transformation. It typically presents with nonspecific clinical symptoms, such as abdominal pain and palpable masses. Diagnosis primarily relies on multimodal imaging combined with histopathological examination. The main treatment strategies include carboplatin- and paclitaxel-based combination chemotherapy, resection of the abdominal wall mass, and hysterectomy with bilateral salpingo-oophorectomy. The uniqueness of this article lies in the patient experimentally receiving treatment with bevacizumab and sintilimab, while not undergoing hysterectomy with bilateral salpingo-oophorectomy. Case Description: This article presents the case of a 48-year-old G2P1 female, with no family history of gynecological cancer, who presented with a progressively enlarging abdominal mass over 1 month at her prior cesarean section scar site, two decades post-procedure. Computed tomography (CT) revealed multiple cystic hypodense lesions within the bilateral rectus abdominis muscles, measuring up to 11.03 cm × 7.64 cm. Her tumor markers were elevated [cancer antigen 125 (CA125): 98.6 U/mL; human epididymis protein 4 (HE4): 74.9 pmol/L]. Histopathological analysis confirmed malignant transformation of AWE into clear cell carcinoma. The patient underwent radical resection of a 15 cm × 15 cm infiltrative mass with 5 mm margins, followed by mesh hernioplasty and abdominal wall reconstruction. Postoperatively, the patient received 6 cycles of 21 days of chemotherapy comprising albumin-bound paclitaxel (300 mg), carboplatin (600 mg), bevacizumab (500 mg), and sintilimab (200 mg). However, pulmonary metastasis was detected 13 months after the completion of adjuvant chemotherapy. Conclusions: This patient was not diagnosed with clear cell carcinoma of the abdominal wall prior to the initial surgery; therefore, hysterectomy and bilateral salpingo-oophorectomy were not performed. Our case highlights the need for increased vigilance toward malignant transformation of AWE, as well as may provide references for the treatment and follow-up of similar cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.